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Purpose: To determine whether activity of carbohydrate metabolism enzymes (aldolase, pyruvate kinase, isocitrate
dehydrogenase, and malate dehydrogenase) are altered in the glaucomatous trabecular meshwork (TM) compared to
controls.
Methods: Tissue specimens were obtained from trabeculectomy (n=45 open angle glaucoma; Caucasian, average age
61±8 years of age of both genders) and from cadaver eyes (n=15 control and n=5 glaucoma; Caucasian, average age 63±4
years of both genders). Protein extracts from TM tissue were prepared in a non-denaturing buffer containing 0.1% genapol.
Aldolase activity was measured spectrophotometrically at 240 nm absorbance using reaction of 3-phosphoglycerate with
hydrazine to form hydrazone. Pyruvate kinase activity was measured by coupling lactate dehydrogenase with NADPH
and pyruvate absorbance was measured at 340 nm. Isocitrate dehydrogenase activity was measured using reduction of
NADP to NADPH at the characteristic absorbance at 340 nm. Malate dehydrogenase catalyzes the interconversion of L-
malate and oxaloacetate using NADP as a coenzyme, quantified by its absorbance at 340 nm.
Results: Aldolase, pyruvate kinase, isocitrate dehydrogenase, and malate dehyrogenase activities in the glaucomatous
TM tissue were found to be reduced 70, 50, 25, and 69 percent, respectively. SDS–PAGE analysis suggests the presence
of 4-hydorxynonenal (HNE) modified isocitrate dehydrogenase protein in the glaucomatous TM tissue compared to
controls.
Conclusions: Several Krebs cycle enzyme activities are considerably reduced in glaucomatous TM. HNE modified
isocitrate dehydrogenase activity is consistent with reduced inactivated form of the protein. Lipid peroxidation product
modification of aldolase, pyruvate kinase, and isocitrate dehydrogenase serves as a likely reason for the reduction of
enzyme activity.
Open angle glaucoma is an irreversible late onset and
progressively  blinding  disease.  The  anatomy  of  anterior
chamber angle, the site of aqueous egress, between iris and
cornea, has been used to differentiate open angle glaucomas
from angle closure glaucomas. Primary open angle glaucoma
(POAG) is established as a way of exclusion when no inciting
condition  can  be  ascribed  to  development  of  open  angle
glaucoma. Glaucomas are termed secondary when they occur
in  association  with  prior  injury  or  concomitant  illness.
Elevated  intraocular  pressure  (IOP)  is  a  risk  factor  for
glaucoma.
Glaucomas  have  been  ascribed  to  an  imbalance  in
aqueous humor production and outflow. Increased resistance
at the level of TM decreases the outflow and leads to elevated
IOP [1]. In POAG increased resistance in TM occurs due to
changes in the TM cells. Several studies have shown that TM
cells  and/or  their  capacity  for  cell  remodeling  undergo
significant alterations. We reasoned that biochemical changes
in  the  TM  have  to  underlie  cellular  changes.  One  of  the
pathomechanisms expected to be involved is the TM energy
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metabolism,  which  affects  other  processes,  such  as  TM
remodeling capacity. We investigated four critical enzymes
of  energy  metabolism  (Krebs  cycle)  in  the  TM.  Previous
reports  elucidated  to  the  role  of  protein  lipid  oxidation
modification  in  the  glaucomatous  optic  nerve  [2-4].  We
provide evidence that lipid peroxidation product modification
reduces the activity of isocitrate dehydrogenase, one of the
key enzymes of the Krebs cycle in the glaucomatous TM.
METHODS
Tissue procurement: Glaucomatous tissue specimens were
obtained from trabeculectomy (n=45 open angle glaucoma;
Caucasian, age range 53–69 years) and from cadaver eyes
(n=5;  Caucasian,  age  range  59–67,  encompassing  both
genders). Cadaver eye derived TM tissue (n=15) from non-
glaucomatous donors of both genders (age range 59–67) were
used as normal controls. Protein extracts from TM tissue were
prepared in a non-denaturing buffer (125 mM Tris-Cl pH 7.0,
100 mM NaCl) containing 0.1% Genapol C-100 (a detergent
used to extract proteins; EMD Biosciences, Inc. La Jolla, CA).
The  research  was  conducted  with  local  IRB  committee
approval, following the tenets of the declaration of Helsinki.
Enzymatic  assays:  Aldolase  converts  fructose-1,6-
bisphosphate  into  dihydroxy  acetone  phosphate  and
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1286glyceraldehyde-3-phosphate.  Aldolase  enzymatic  activity
assay  was  measured  using  the  Bayer  modification  of  the
hydrazine assay; 3-phosphoglycerate reacts with hydrazine to
form  hydrazone.  Hydrazone  absorbs  at  240  nm  and  is
quantified spectrophotometrically [5].
Pyruvate kinase catalyzes the conversion of phosphoenol
pyruvate plus ADP into pyruvate plus ATP. The reaction
kinetics  were  quantified  by  coupling  with  lactate
dehydrogenase NADH + pyruvate resulting form lactate +
nicotinamide adenine dinucleotide (NAD). Enzyme activity
can be measured at 340 nm absorbance by spectrophotometry
[6,7].
Isocitrate  dehydrogenase  catalyzes  the  conversion  of
isocitrate  into  α-ketoglutarate  and  carbon  dioxide.
Simultaneously  NADP  is  reduced  into  NADPH.
Characteristic  NADPH  absorbance  quantifies  the  enzyme
activity at 340 nm [6,8]. The assays were standardized with
aldolase and pyruvate kinase, L-lactic acid dehydrogenase and
glutamic dehydrogenase (A8811, P7768, L1254, and G2501;
Sigma Chemical Co., St. Louis, MO).
Malate dehydrogenase catalyzes the interconversion of
L-malate and oxaloacetate using NAD as a coenzyme [9].
Malate dehydrogenase activity was determined by measuring
decreased absorbance at 340 nm resulting from the oxidation
of NADH at 25 °C in 100 mM potassium phosphate buffer pH
7.4 and 6 µM oxaloacetic acid. The malate activity in 10 µg
of total tissue extract protein (from glaucomatous and normal
TM) was expressed as 10-fold decrease in absorbance and
expressed  as  relative  absorbance.  Our  assay  does  not
distinguish between mitochondrial or cytosolic enzymes and
provides a gross measure of malate dehydrogenase activity.
For all activity assays statistical analysis was performed
within each group (each group comprised of 10 different tissue
samples) and compared to 0.0 using the two tailed one-sample
t-test.
Western  analyses:  Protein  was  quantified  using  the
biochinchonic  acid  (BCA)  protein  assay  (Pierce
Biotechnology Inc. Rockford, IL). Western blot analysis was
performed with 5 µg of protein on 4%–20% Tris-Glycine gels
(Invitrogen Inc., Carlsbad, CA). After fractionation, proteins
were electro-blotted onto a polyvinylidene fluoride (PVDF)
membrane  (Millipore,  Billerica,  MA)  using  standard
procedures  and  probed  with  commercially  available  HNE
protein adduct antibody generated in mouse (1:1,000 dilution;
NOF  Corporation  Tokyo,  Japan),  GAPDH  antibody
(MAB374; at 1:3 000 dilution); aldolase antibody (AB1809;
at  1:1,000  dilution),  pyruvate  kinase  antibody  (1:1,000
dilution; AB1235; Chemicon International) and polyclonal
antibody  to  isocitrate  dehydrogenase  (1:1,000  dilution;
PAB-01173; Orbigen Inc.). All secondary antibodies were
diluted at 1:1,000.
Mass  spectrometry:  To  identify  the  proteins  and  perform
quantification, 80 µg of sample tissue were loaded on to 4%–
20% SDS–PAGE gels. Protein bands thus separated were
excised,  destained  with  50%  acetonitrile  /water,  and
suspended in 0.5 M triethylammoniumbicarbonate (TEAB;
number 17902; Sigma Chemical Co.) pH 8.5 and reduced with
10  mM  Tris-(2-Carboxyethyl)  phosphine  (TCEP;  Sigma
Chemical Co.). The proteins were subsequently alkylated in
the dark using 55 mM solution of iodoacetamide (Catalog No-
RPN6302V; GE Healthcare Inc., Buckinghamshire, England)
and in-gel digested with sequencing grade modified trypsin
(0.1 µg/15 µl in 15 mM N-Ethylmorpholin; catalog number
V5113;  Promega  Corporation,  Madison,  WI)  overnight  at
37 °C. The peptides were extracted twice with 50 µl 0.1%
triflouroracetic acid/60% acetonitrile and finally with 30 µl of
acetonitrile and dried in a SpeedVac. The extracted peptides
were incubated with the iTRAQ Rg-8-Plex Assay kit reagents
(Applied  Biosystems,  Foster  City, CA).   Separate peptides
were  isolated  from  different  bands  and  incubated  with
reagents 113, 114, 115, and 116 (ABI, Foster City, CA) for
peptides derived from control TM protein bands, and with
reagents 117, 118, 119, and 121 for peptides derived from
glaucomatous TM protein bands in 0.5 M TEAB containing
60% v/v isopropanol. The incubation mixtures were dried in
a SpeedVac, mixed together and loaded onto a slurry of 500 µl
of cation exchange buffer in 12 mM ammonium formate in
25%  acetonitrile  at  pH  2.5–3.0,  and  separated
chromatographically.
Two-dimensional  liquid  chromatography  (2D-LC)
separations: 2D-LC is performed to achieve better separation
of  peptides  before  mass  spectrometry.  Peptides  recovered
after in-gel digestion were labeled with iTRAQ reagents and
then subjected to Strong Cation Exchange (SCX) separation..
SCX  peptide  separations  were  performed  on  a  passivated
Waters  600E  HPLC  system,  using  a  4.6×250  mm
polysulfethyl aspartamide column (PolyLC, Columbia, MD)
at  a  flow  rate  of  1  ml/min.  Buffer  A  contained  10  mM
ammonium formate, pH 2.7, in 20% Acetonitrile/80% water.
Buffer B contained 666 mM ammonium formate, pH 2.7, in
20% acetonitrile/80% water. The gradient was Buffer A at
100% (0–22 min following sample injection), 0% to 40%
Buffer B (16–48 min), 40% to 100% Buffer B (48–49 min),
then isocratic 100% Buffer B (49–56 min), then at 56 min
switched back to 100% Buffer A to re-equilibrate for the next
injection.  The  first  26  ml  of  eluant  (containing  all  flow-
through fractions) was combined into one fraction, then 14
additional 2-ml fractions were collected. SCX fractions were
dried down completely to reduce volume and to remove the
volatile ammonium formate salts, then resuspended in 9 µl of
2% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic acid before
second dimension separation on reverse phase C18 nanoflow-
LC.
For the second dimension separation by reverse phase
nanoflow LC, each SCX fraction was autoinjected onto a
Chromolith CapRod column (150×0.1 mm; Merck) using a
5 µl injector loop on a Tempo LC MALDI Spotting system
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1287(ABI-MDS/Sciex).  Buffer  C  consisted  of  2%  acetonitrile,
0.1%  trifluoroacetic  acid,  and  Buffer  D  contained  98%
acetonitrile, 0.1% trifluoroacetic acid. The elution gradient
was 95% C/5% D (2 µl per min flow rate from 0 to 3 min, then
2.5 µl per min from 3 to 8.1 min), 5% D to 38% D (8.1–40
min), 38% D to 80% D (41–44 min), 80% D to 5% D (44–49
min; initial conditions). Flow rate was 2.5 µl/min during the
gradient, and an equal flow of MALDI matrix solution was
added post-column (7 mg/ml recrystallized CHCA (A-Cyano-
Hydroxycinnamic  Acid),  2  mg/ml  ammonium  phosphate,
0.1% trifluoroacetic acid, 80% acetonitrile). The combined
eluant was automatically spotted onto a stainless steel MALDI
target plate every 6 s (0.6 µl per spot), for a total of 370 spots
per original SCX fraction.
Mass  spectrometric  quantification:  The  sample  spots
mentioned above were dryed and thirteen calibrant spots (ABI
4700 Mix) were added to each plate manually. MALDI target
plates (15 per experiment) were analyzed in a data-dependent
manner on an ABI 4800 MALDI TOF-TOF. As each plate is
entered into the instrument, a plate calibration/ MS Default
calibration update is performed, and then the MS/MS default
calibration is updated. MS spectra were taken from 5,500
MALDI Spots, averaging 500 laser shots per spot at Laser
Power 3100. A total of 3,249 MS/MS spectra were taken with
up to 2,500 laser shots per spectrum at Laser Power 3600, with
CID gas Air at 1.2 to 1.3×10−6 Torr. After the MS and MS/MS
spectra from all 15 plates in a sample set were acquired,
protein identification and quantitation was performed using
the Paragon algorithm as implemented in ProteinPilot 3.0
software (Applied Biosystems/MDS-SCIEX Joint Venture,
Foster  City,  CA)  and  Matrix  Sciences  Mascot  algorithm
version 2.1. ProteinPilot software was used for searches with
the  following  search  parameters:  Cys  Alkylation  –
Iodoacetamide; ID Focus – Biologic Modifications; Search
Effort – Thorough. The Jan 1st 2010 Human NCBI database
Sequences containing 512,785 Protein Sequences, plus 156
common laboratory contaminants. For estimation of “False
Discovery Rate” (FDR), simultaneous search was performed
on a concatenated Decoy database which is the exact reverse
of each protein sequence in the database plus 156 common
human and laboratory contaminants. Protein identifications at
95% confidence level were retained. The preset “Thorough”
(iTRAQ or Identification) search settings were used where
identifications must have a ProteinPilot Unused Score >1.3
(>95% confidence interval). In addition, the only protein IDs
accepted had a FDR estimation of less than 5%, as calculated
from the slope of the accumulated Decoy database hits by the
PSPEP  (Proteomics  System  Performance  Evaluation
Pipeline) program [10]. This FDR estimate is much more
stringent than p<0.05 or 95% confidence scores in Mascot,
Sequest, ProteinPilot, or the aggregate False Discovery Rate
estimations (2× number of Decoy database IDs/Total IDs at
any chosen threshold score) commonly used in the literature.
Combined  with  the  ProGroup  algorithm  included  in
ProteinPilot  the  FDR  gives  a  very  conservative  and  fully
MIAPE-compliant list of proteins identified.
RESULTS AND DISCUSSION
Oxidative  stress  has  been  implicated  to  cause  damage  to
nearly all tissues including trabecular meshwork. Here, we
describe that oxidation products may reduce the enzymatic
activities of energy metabolism and may become part of the
damage process. Thus initial oxidative damage and generated
products may have a magnified dampening effect of damage.
The  activity  measurements  were  performed  using
standard assay systems for each enzyme for 10 samples per
group: normal control and primary open angle glaucoma. All
normal TM tissue samples were derived from cadaver eyes
from National Disease Research Interchange, Philadelphia,
PA. The ophthalmic details for normal eyes followed the
tissue  delivery.  Thus  more  (about  16  eyes)  samples  were
collected and assayed but only those were included for which
details showed definite evidence of ocular health and absence
of  disease.  The  trabecular  meshwork  aldolase,  pyruvate
kinase, isocitrate dehydrogenase, and malate dehydrogenase
activities in the glaucomatous TM tissue were found to be
reduced 70, 50, 25, and 69 percent, respectively (Figure 1A-
D).  Decreased  activity  is  consistent  with  inactivating
modification  or  degradation  of  proteins  in  glaucoma.
Microarray studies (GEO accession number GDS359) have
been performed by several groups using glaucomatous and
normal trabecular meshwork tissue. These microarray studies
did not show any discernable difference in the expression level
of  aldolase  and  pyruvate  kinase  at  the  mRNA  level.  Our
quantitative proteomic analysis also showed decreased levels
of aldolase, pyruvate kinase, isocitrate dehydrogenase, and
malate  dehydrogenase  which  is  consistent  with  activity
measurement (Table 1). We did detect the peptides of the
enzymes  from  excised  protein  bands  that  were  also
immunoreactive for 4-hydroxynonenal (HNE), however, we
failed to detect the modified peptides. Our failure to detect the
modified peptides may be due to the use of trypsin in the
processing of tissues. The failure of detection is explicable
based on the possibility that modification might involve lysine
and arginine residues which will then not be digested by
trypsin.  Another  possibility  is  relative  low  abundance  of
modified residues. The lipid peroxidation modified proteins
have been shown to undergo rapid degradation [2]. Although
western  analysis  will  detect  the  modification  due  to
amplification but it will be difficult to capture the modified
peptides by mass spectrometry. Another complication that
will  also  evade  capture  by  mass  spectrometry  is
heterogeneous nature of modification on proteins that will
generate a large ensemble of different peptides each with a
modification  or  the  same  peptide  with  a  modification  on
different residues.
Lipid oxidation products have been implicated to cause
damage to the aqueous drainage system [11]. Our SDS–PAGE
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1288analysis suggests the presence of HNE modified isocitrate
dehydrogenase  protein  in  the  glaucomatous  TM  tissue
compared  to  controls  (Figure  2).  Two  identical  gel
electrophoretic  separations  were  performed,  protein  bands
immunoreactive for isocitrate dehydrogenase were excised
and subsequently submitted to electrophoresis in a second
4%–20% SDS–PAGE and probed with antibodies to isocitrate
dehydrogenase and HNE. The identical gel was probed with
antibodies  to  isocitrate  dehydrogenase,  HNE  and
glyceraldehyde-3-dehydrogenase  (GAPDH).  Western
analysis also revealed presence of isocitrate dehydrogenase
and  other  enzymes  at  relatively  high  molecular  weights
indicating aggregate formation as well as locations in gel
corresponding to molecular weights lower than the bona fide
molecular weights of the proteins consistent with degradation
of the proteins (data not shown). However, these analyses
necessitated much higher protein loads and longer exposure
of detection reagents. While they were thus detected severe
darkening of the film overall suggests relative low abundance
of aggregated and degraded proteins. Such aggregated and
degraded  proteins  were  more  frequent  and  abundant  in
glaucomatous than normal TM. It is important to note that
Figure 1. Representative enzymatic activity analyses for aldolase, pyruvate kinase and isocitrate dehydrogenase. Activity measurements were
performed on 10 TM tissue samples (5 µg total protein each) derived from normal (dotted bars) or glaucomatous donors (hollow bars).
Colorimetric assay was performed for determination of enzymatic activities and standard deviation from 10 individual measurements have
been presented. A: Activity assay for aldolase, B: Activity assay for pyruvate kinase, and C: Activity assay measurement for isocitrate
dehydrogenase.  D:  Activity  assay  for  malate  dehydrogenase.  Each  bar  represents  the  mean±standard  deviation  from  ten  independent
experimental readings (ten samples in each group) and was found significantly different from 0.0 for each activity measurement by the one-
sample t-test. The asterisk indicates a p<0.05.
TABLE 1. SELECT ENERGY METABOLISM ENZYMES DOWN-REGULATED IN GLAUCOMATOUS TM.
Accession
number Protein
Peptide
matches***
          iTRAQ ratio
(Glaucomatous/ Normal)*
Sequence coverage
(%) SD**
P40925 Malate Dehydrogenase,cytoplasmic 10 0.51 37 0.023
P40926 Malate Dehydrogenase, mitochondrial 10 0.83 40 0.026
P04075 Aldolase 4 0.34 21 0.031
O75874 Isocitrate Dehydrogenase 4 0.62 9 0.007
P14786 Pyruvate kinase,M2 isozyme 4 0.42 9 0.028
The asterisk indicates that the iTRAQ ratio of glaucomatous (labeled with 117–199, 121) with normal (113–116) has been
shown. The  double asterisk indicates the standard deviation of percentage error from multiple iTRAQ measurement. The triple
asterisk  indicates  that  the  identified  peptides  of  different  proteins  against  their  accession  numbers  are:  P40925:
FVEGLPINDFSR; GEFVTTVQQR; ESAFEFLSSA; EVGVYEALK; ENFSCLTR; LSSAMSAAK; SQGAALDK; DDSWLK;
DVIATDK;  ELTEEK;  P40926:  VDFPQDQLTALTGR;  AGAGSATLSMAYAGAR;  GYLGPEQLPDCLK;
FVFSLVDAMNGK; GCDVVVIPAGVPR; EGVVECSFVK; IQEAGTEVVK; VSSFEEK; NSPLVSR; KPGMTR; P04075:
PYQYPALTPEQK;  GILAADESTGSIAK;  QLLLTADDR;  VLAAVYK;  O75874:  NILGGTVFR;  IIWELIK;  SQFEAQK;
GLPNVQR; P14786: GDLGIEIPAEK; GSGTAEVELK; VNFAMNVGK; GIFPVLCK.
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1289modification of calpain-1 by isolevuglandin, another lipid
peroxidation  product  was  previously  observed  in  the
trabecular  meshwork,  and  was  associated  with  both
aggregated and degraded calpain-1 [12].
Previously, human growth hormone and its interplay with
carbohydrate metabolism have been implicated in open angle
glaucoma [13]. Investigations with iodoacetamide, however,
were thought not to inhibit energy metabolism [14]. Recently
the interest in damage to trabecular meshwork mitochondrial
complex proteins and energy metabolism has revived [15,
16].  We  show  here  a  significant  decrease  in  activities  of
aldolase,  pyruvate  kinase,  and  isocitrate  dehydrogenase
commensurate with decreased levels of proteins revealed by
quantitative  proteomic  analysis.  We  used  the  following
iTRAQ reagents (tags 113–116 for normal and 117–119 and
121;  ABI  Inc.)  that  showed  a  lower  ratio  of  peptides  in
glaucomatous  compared  to  normal  TM  (Table  1).  The
sequence coverage of proteins ranged from 9%–40% and the
ratio was consistently lower in glaucomatous compared to
normal TM (Table1). The ability to capture the aggregated
and degraded peptides of these enzymes was likely impaired
as detailed above. It is important to note that a low abundance
of  these  enzymes  and  even  lower  abundance  of  their
aggregates  and  degraded  products  are  supported  by  their
relative lack of detection in the western blot compared to
calpain-1 or isolevuglandin (iso[4]LGE2) modified products
of calpain-1 that we have previously detected in the TM [12].
It is likely that an abundance of aggregated and degraded
proteins was low in the TM tissue or that such aggregated and
degraded  products  are  cleared  faster.  Therefore  their
accumulated levels in the tissue is relatively low. Quantitative
proteomics with iTRAQ reagents enabled us to evaluate with
a  great  degree  of  confidence  that  the  levels  of  selected
metabolic  enzymes  are  lower  in  glaucomatous  TM  tissue
compared to controls (Table 1). This correlates functionally
with lower activity levels for these enzymes (Figure 1). In the
future, we will attempt the identify specific sites of HNE
modification of these enzymes.
In  summary,  together  with  HNE  modification  of
isocitrate  dehydrogenase,  our  results  show  that  energy
metabolism enzymes may potentially have reduced activity
due  to  modification  or  degradation  by  cellular  enzyme
cascades in POAG.
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